

IN THE CLAIMS:

Please cancel claims 163-165 and 173-174 without prejudice to Applicants' right to pursue protection for the cancelled subject matter in a later filed divisional or continuation application.

Please amend claim 145, without prejudice, as follows:

Claims 1-140. (Cancelled).

Claim 141. (Previously Presented) A method for treating or preventing a neoplasia disorder in a mammal in need of such treatment or prevention, which method comprises administering to said mammal a therapeutically-effective amount of a combination of celecoxib and an integrin antagonist selected from the group of compounds consisting of:

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy)-2-pyrimidinyl]amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-b-alanine; and

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine.

Claims 142. – 143. (Cancelled).

Claim 144. (Previously Presented) A combination comprising celecoxib and an integrin antagonist selected from the group of compounds consisting of:

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy)-2-pyrimidinyl]amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-b-alanine;

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-b-alanine; and

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine.

Claim 145. (Currently Amended) The method of claim 141 wherein the neoplasia disorder is selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, ~~capillary~~, carcinoids, carcinoma, carcinosarcoma, ~~eavernous~~, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ~~ependymal~~, ~~epitheloid~~, Ewing's sarcoma, ~~fibrolamellar~~, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangioblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia, interepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, leiomyosarcoma, lentigo maligna melanomas, malignant melanomas, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, ~~meningeal~~, ~~mesothelial~~, metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma, nodular melanoma, oat cell carcinoma, ~~oligodendroglial~~, osteosarcoma, ~~pancreatic polypeptide~~, papillary serous adenocarcinoma, ~~pineal cell~~, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, ~~submesothelial~~, superficial spreading melanoma, undifferentiated cardinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

Claim 146. (Previously Presented) The method of claim 141 wherein the neoplasia disorder is lung cancer.

- | | |
|-----------------------------------|---|
| Claim 147. (Previously Presented) | The method of claim 141 wherein the neoplasia disorder is colorectal cancer. |
| Claim 148. (Previously Presented) | The method of claim 141 wherein the neoplasia disorder is breast cancer. |
| Claim 149. (Previously Presented) | The method of claim 141 wherein the neoplasia disorder is prostate cancer. |
| Claim 150. (Previously Presented) | The method of claim 141 wherein the neoplasia disorder is bladder cancer. |
| Claim 151. (Previously Presented) | The method of claim 141 wherein the neoplasia disorder is ovary cancer. |
| Claim 152. (Previously Presented) | The method of claim 141 wherein the neoplasia disorder is cervical cancer. |
| Claim 153. (Previously Presented) | The method of claim 141 wherein the neoplasia disorder is gastrointestinal cancer. |
| Claim 154. (Previously Presented) | The method of claim 141 wherein the neoplasia disorder is head and neck cancer. |
| Claim 155. (Previously Presented) | The method of claim 141 wherein the integrin antagonist is (3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine. |
| Claim 156. (Previously Presented) | The method of claim 141 wherein the integrin antagonist is (3R)-N-[[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine. |
| Claim 157. (Previously Presented) | The method of claim 141 wherein the integrin antagonist is (3R)-N-[[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine. |
| Claim 158. (Previously Presented) | The method of claim 141 wherein the integrin antagonist is (3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine. |
| Claim 159. (Previously Presented) | The method of claim 141 wherein the integrin antagonist is (3R)-N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy)-2-pyrimidinyl]amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine. |
| Claim 160. (Previously Presented) | The method of claim 141 wherein the integrin antagonist is (3R)-N-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine. |
| Claim 161. (Previously Presented) | The method of claim 141 wherein the integrin antagonist is (3R)-N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine. |

Claim 162. (Previously Presented) The method of claim 141 wherein the integrin antagonist is (3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-b-alanine.

Claims 163. – 165. (Cancelled).

Claim 166. (Previously Presented) The combination of claim 144 wherein the integrin antagonist is (3R)-N-[[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine.

Claim 167. (Previously Presented) The combination of claim 144 wherein the integrin antagonist is (3R)-N-[[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine.

Claim 168. (Previously Presented) The combination of claim 144 wherein the integrin antagonist is (3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine.

Claim 169. (Previously Presented) The combination of claim 144 wherein the integrin antagonist is (3R)-N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy)-2-pyrimidinyl]amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine.

Claim 170. (Previously Presented) The combination of claim 144 wherein the integrin antagonist is (3R)-N-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine.

Claim 171. (Previously Presented) The combination of claim 144 wherein the integrin antagonist is (3R)-N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine.

Claim 172. (Previously Presented) The combination of claim 144 wherein the integrin antagonist is (3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-b-alanine.

Claims 173. – 174. (Cancelled).